reason report
outlook move lower covid impact mask underli
bottom line share trade today reaction manag
commentari post-earn call patient util
month earli march covid
util trend still impli growth deceler comp-adjust
basi show improv mid-single-digit rang post
american heart associ aha present mid-novemb
estim mid-single-digit decemb encourag
admittedli difficult build high level confid near-
term sustain trend continu improv
underli busi ex covid week data
easier y/i compar point physician educ
initi -- move virtual covid -- potenti drive
might start stabil on-going covid impact
-- like dramat fy sale april
accord manag -- like near-term cloud
base busi trend believ least quarter two make
difficult discern might sustain growth outlook ex
covid also highlight pipelin clinic
progress fr collaps sheath approv like year-
end feasibl studi fr impella ecp set start year
releas public full protect dataset
look restore-ef single-arm studi look eject fraction
key metric patient fall product innov
help clinic data import still worri could
take random control trial cardiogen shock
high risk pci turn tide meaning back sustain
double-digit adopt ramp impella
growth outlook steadi state basi like suppress
next quarter -- mayb even year --
see definit data stock perspect today ralli put
valuat nearli sale meaning premium vs
smid-cap med-tech group trade sale tough
argu ev/sal multipl would appropri tri
assess valuat inclin think deserv trade
premium long-term given double-digit sale growth profil margin
profil strong balanc sheet still even appli premium --
use sale -- put valuat impli share
basic fairli valu
medic suppli devic
ev/sal multipl
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu dilut gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
reiter mp pt price target vs prior appli
ev/sal multipl now-low estim
assum modest contract current level
sale still smid-cap group averag continu believ
long-term sale growth outlook profit warrant
multipl premium vs smid-cap coverag univers averag
lower y/i previous impella
sale y/i driven covid manag commentari
post-earn call impli dramat sale impact
reflect recent estim updat
revenu move y/i
breeth acquisit highli strateg ahead earn
announc acquisit breeth -- privat held develop
deal make strateg sens manag note
impella patient also requir oxygen patient
alreadi treat ecpella ecmo impella
submit clearanc limit launch expect
rate share market perform price target continu
believ clinic util impella -- eventu return compani sustain
double-digit growth profil adopt re-ramp highli under-penetrated --
believ aha american heart associ data present subsequ
public circul jama exacerb alreadi seem rise
concern around patient select oper experi associ risk
make re-ramp usag difficult near term without random control clinic
trial announc undertak trial like sever year
actual see meaning data combat current neg nois
relat covid worri even now-low sale estim may fulli
reflect impact medacorp physician convers suggest signific declin even
emerg coronari volum -- cardiogen shock -- impli perhap even seemingli
protect revenu stream total impella sale might see dramat cut
current anticip
lastli relat potenti upcom catalyst expect releas ipp propos
day medacorp check suggest recent neg dataset could
catch attent agenc necessarili posit directli appli data
reimburs cut note last two year propos meaning cut
revers extent -- flat slightli vs propos cut
basic flat vs propos cut also analyst meet schedul
may manag could posit highlight
outlin detail pipelin key initi undertak counter-detail
recent neg data check compani obvious longer
hold meet person explor option hold analyst meet virtual
price target vs prior appli ev/sal multipl now-low
estim assum modest contract current level
sale still smid-cap group averag continu believ long-term
sale growth outlook profit warrant multipl premium vs smid-cap coverag
univers averag
risk rate valuat includ failur drive increas util rate
and/or continu add new account steadi rate failur execut pipelin
launch new geographi potenti reimburs declin potenti competit
pvad product secur approv gain meaning market share potenti
dollar million except per share data
total good sold
research develop expens
consensu incom statement item includ contributor factset
revenu
servic revenu
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
total good sold
research develop
revenu
consensu incom statement item includ contributor factset
servic revenu
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
total good sold
research develop expens
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
pivot compar today standard care immedi reperfus without
ecp expand cardiac power true cathet target three
liter flow ideal pump high-risk pci physician want
anyth larger way pump short
area inflow valv thin soft membran abras
valv ecp deliv design clinic durat
hour fr pump expand fr
bridg
impella btr expect later outer year estim flow l/min
cathet fr pump shorter design durat month year
also wearabl driver allow patient get discharg
hospit impella btr minim invas approach axillari arteri
 jan close final
detail trial fda expect
start second half
 manag expect first patient octob
 octob manag expect
first patient next three week
 februari stemi trial enrol
patient site
plan begin enrol octob
still pre-clin test aug
-a februari first-in-man ecp still
expect
 jan first-in-man ecp expect
 octob manag expect
first patient end march
expand sheath expand collaps around cathet
end
 februari treat
patient expand sheath
